Company Search:
Advanced Search
Sponsored Links
Gilead Sciences, Inc. Company Snapshot
Gilead Sciences, Inc. operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Gilead Sciences with three other companies in this sector in the United States: Biogen Inc (2018 sales of $13.45 billion of which 81% was Product revenues, net), Grifols SA ($5.29 billion of which 78% was Bioscience), and Amgen Inc. ($23.75 billion of which 21% was Enbrel).

Sales Analysis. Gilead Sciences reported sales of $22.13 billion for the year ending December of 2018. This represents a decrease of 15.2% versus 2017, when the company's sales were $26.11 billion.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Gilead Sciences, Inc.
  Stock Performance Chart for Gilead Sciences, Inc.
  Stock Data: Recent Stock Performance:
  Current Price (10/11/2019): 63.99
(Figures in U.S. Dollars)
1 Week 2.3%   13 Weeks -3.8%  
4 Weeks -3.4%   52 Weeks -13.0%  
Gilead Sciences, Inc. Key Data:
  Ticker: GILD Country: United States
  Exchanges: NAS FRA MXK Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2018 Sales 22,127,000,000
(Year Ending Jan 2019).
Employees: 11,000
  Currency: U.S. Dollars Market Cap: 81,040,486,229
  Fiscal Yr Ends: December Shares Outstanding: 1,266,455,481
  Share Type: Common Closely Held Shares: 6,870,968
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.